Otsuka's sibeprenlimab achieves positive phase 3 results for IgAN

** Otsuka Holdings (TSE:4578) subsidiary, Otsuka Pharmaceutical, has announced positive results from the Phase 3 VISIONARY study evaluating sibeprenlimab for the treatment of Immunoglobulin A Nephropathy (IgAN) in adults. The study demonstrated a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months compared to placebo. The data were presented at the European Renal Association (ERA) Congress.